Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) EBT Margin (2020 - 2026)

Insight Molecular Diagnostics' EBT Margin history spans 6 years, with the latest figure at 2057.51% for Q4 2025.

  • On a quarterly basis, EBT Margin rose 20541.0% to 2057.51% in Q4 2025 year-over-year; TTM through Dec 2025 was 1260.76%, a 197703.0% increase, with the full-year FY2025 number at 1260.76%, up 198437.0% from a year prior.
  • EBT Margin hit 2057.51% in Q4 2025 for Insight Molecular Diagnostics, up from 4249.23% in the prior quarter.
  • Over the last five years, EBT Margin for IMDX hit a ceiling of 2006.4% in Q1 2023 and a floor of 11752.17% in Q3 2024.
  • Historically, EBT Margin has averaged 2558.95% across 5 years, with a median of 1849.89% in 2023.
  • Biggest five-year swings in EBT Margin: soared 5414713bps in 2021 and later crashed -1023959bps in 2024.
  • Tracing IMDX's EBT Margin over 5 years: stood at 997.16% in 2021, then crashed by -340bps to 4385.77% in 2022, then dropped by -16bps to 5092.99% in 2023, then soared by 56bps to 2262.92% in 2024, then rose by 9bps to 2057.51% in 2025.
  • Business Quant data shows EBT Margin for IMDX at 2057.51% in Q4 2025, 4249.23% in Q3 2025, and 1900.0% in Q2 2025.